These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 36336975)

  • 1. Prognostic modeling of cutaneous melanoma stage I patients using cancer registry data identifies subsets with very-low melanoma mortality.
    Eguchi MM; Elder DE; Barnhill RL; Piepkorn MW; Knezevich SR; Elmore JG; Kerr KF
    Cancer; 2023 Jan; 129(1):89-97. PubMed ID: 36336975
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Breslow thickness and clark level in melanoma: support for including level in pathology reports and in American Joint Committee on Cancer Staging.
    Marghoob AA; Koenig K; Bittencourt FV; Kopf AW; Bart RS
    Cancer; 2000 Feb; 88(3):589-95. PubMed ID: 10649252
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mortality burden and prognosis of thin melanomas overall and by subcategory of thickness, SEER registry data, 1992-2013.
    Landow SM; Gjelsvik A; Weinstock MA
    J Am Acad Dermatol; 2017 Feb; 76(2):258-263. PubMed ID: 27887797
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Melanoma of the external ear: A population-based study.
    Deep NL; Glasgow AE; Habermann EB; Kasperbauer JL; Carlson ML
    Am J Otolaryngol; 2017; 38(3):309-315. PubMed ID: 28258767
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical and histopathologic predictors of survival in patients with malignant melanoma: a population-based study in Sweden.
    Thörn M; Pontén F; Bergström R; Sparén P; Adami HO
    J Natl Cancer Inst; 1994 May; 86(10):761-9. PubMed ID: 8169974
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Should all patients with melanoma between 1 and 2 mm Breslow thickness undergo sentinel lymph node biopsy?
    Mays MP; Martin RC; Burton A; Ginter B; Edwards MJ; Reintgen DS; Ross MI; Urist MM; Stromberg AJ; McMasters KM; Scoggins CR
    Cancer; 2010 Mar; 116(6):1535-44. PubMed ID: 20108306
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic variables and prognostic groups for malignant melanoma. The information from Cox and Classification And Regression Trees analysis: an Italian population-based study.
    Crocetti E; Mangone L; Lo Scocco G; Carli P
    Melanoma Res; 2006 Oct; 16(5):429-33. PubMed ID: 17013092
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lymphatic invasion identified by monoclonal antibody D2-40, younger age, and ulceration: predictors of sentinel lymph node involvement in primary cutaneous melanoma.
    Niakosari F; Kahn HJ; McCready D; Ghazarian D; Rotstein LE; Marks A; Kiss A; From L
    Arch Dermatol; 2008 Apr; 144(4):462-7. PubMed ID: 18427039
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Epidemiology of malignant melanoma in central Europe: risk factors and prognostic predictors. Results of the Central Malignant Melanoma Registry of the German Dermatological Society.
    Garbe C; Orfanos CE
    Pigment Cell Res; 1992; Suppl 2():285-94. PubMed ID: 1409431
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Age as a prognostic factor in the malignant melanoma population.
    Austin PF; Cruse CW; Lyman G; Schroer K; Glass F; Reintgen DS
    Ann Surg Oncol; 1994 Nov; 1(6):487-94. PubMed ID: 7850555
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic factors in melanoma patients with tumor-negative sentinel lymph nodes.
    Egger ME; Bhutiani N; Farmer RW; Stromberg AJ; Martin RC; Quillo AR; McMasters KM; Scoggins CR
    Surgery; 2016 May; 159(5):1412-21. PubMed ID: 26775577
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Sentinel lymph node biopsy in patients with melanoma].
    Tomás-Mallebrera L; Rojo-España R; Marquina-Vila A; Gimeno-Clemente N; Morales-Suárez-Varela MM
    Actas Dermosifiliogr; 2010 Jun; 101(5):428-36. PubMed ID: 20525486
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The sentinel lymph node status is an important factor for predicting clinical outcome in patients with Stage I or II cutaneous melanoma.
    Statius Muller MG; van Leeuwen PA; de Lange-De Klerk ES; van Diest PJ; Pijpers R; Ferwerda CC; Vuylsteke RJ; Meijer S
    Cancer; 2001 Jun; 91(12):2401-8. PubMed ID: 11413531
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Acral Lentiginous Melanoma: Incidence and Survival in the United States, 2006-2015, an Analysis of the SEER Registry.
    Huang K; Fan J; Misra S
    J Surg Res; 2020 Jul; 251():329-339. PubMed ID: 32208196
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Thin melanoma.
    Elder DE
    Arch Pathol Lab Med; 2011 Mar; 135(3):342-6. PubMed ID: 21366458
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of ulceration in stages I to III cutaneous melanoma as staged by the American Joint Committee on Cancer Staging System: an analysis of the German Central Malignant Melanoma Registry.
    Eigentler TK; Buettner PG; Leiter U; Garbe C;
    J Clin Oncol; 2004 Nov; 22(21):4376-83. PubMed ID: 15514379
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development and Validation of a Modified Pathologic Nodal Classification System for Cutaneous Melanoma.
    Nguyen AT; Luu M; Nguyen VP; Hamid O; Faries MB; Gharavi NM; Lu DJ; Mallen-St Clair J; Ho AS; Zumsteg ZS
    JAMA Surg; 2021 Nov; 156(11):e214298. PubMed ID: 34468697
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predicting sentinel node status in AJCC stage I/II primary cutaneous melanoma.
    Kruper LL; Spitz FR; Czerniecki BJ; Fraker DL; Blackwood-Chirchir A; Ming ME; Elder DE; Elenitsas R; Guerry D; Gimotty PA
    Cancer; 2006 Nov; 107(10):2436-45. PubMed ID: 17058288
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Action profiles of predictors of death and survival time in stage I malignant melanoma.
    Helfenstein U; Schuler G; Morf S; Schuler D
    Dermatology; 1996; 192(1):1-7. PubMed ID: 8832942
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.